| ERAN | BSRBR | |
---|---|---|---|
TNF inhibitor | Non-biologic | ||
Total subjects | 828 | 9905 | 2581 |
Age, years | 57 (14) | 56 (12) | 60 (12) |
Female sex | 67% | 76% | 73% |
BMI, kg/m2 | 27.6 (5.3) | 27.0 (7.3) | 27.4 (6.7) |
Smoking status | |||
 Never | 39% | 40% | 38% |
 Ex-smoker | 25% | 38% | 41% |
 Current | 36% | 22% | 21% |
 Duration, years | 0.7 (0.6) | 13 (10) | 10 (10) |
Positive serology | 60% | 65% | 57% |
1987 ACR criteria, yes | 53% | 100% | 100% |
DAS28-ESR | 4.7 (1.5) | 6.6 (1.0) | 5.1 (1.3) |
ESR, mm/h | 30 (24) | 46 (29) | 34 (24) |
SJC, 0–28 | 6 (5) | 11 (6) | 6 (5) |
TJC, 0–28 | 7 (7) | 16 (7) | 8 (7) |
VAS, 0–100 | 44 (25) | 72 (20) | 54 (24) |
HAQ, 0–3 | 1.1 (0.8) | 2.0 (0.6) | 1.5 (0.8) |
SF-36 | |||
 Physical function | 30 (15) | 16 (11) | 24 (11) |
 Bodily pain | 33 (11) | 25 (7) | 31 (9) |
 Vitality | 42 (11) | 33 (10) | 39 (10) |
 Mental health | 46 (11) | 40 (11) | 45 (11) |
 PCS | 29 (12) | 16 (8) | 24 (11) |
 MCS | 47 (12) | 44 (11) | 48 (11) |
DMARD by 6-month follow-up | 91% | 100% | 100% |
First recorded DMARD | |||
 MTX monotherapy | 48% | 40% | 0% |
 SSZ monotherapy | 31% | 14% | 0% |
 MTX combination | 12% | 25% | 0% |
 Biologic | 0% | 0% | 100% |